Exicure (NASDAQ:XCUR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Exicure (NASDAQ:XCUR) to a hold rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Exicure Price Performance

Shares of NASDAQ XCUR opened at $6.22 on Friday. The business has a fifty day moving average price of $5.31 and a 200 day moving average price of $5.47. Exicure has a 1-year low of $3.10 and a 1-year high of $15.91. The stock has a market capitalization of $39.62 million, a P/E ratio of -1.68 and a beta of 4.06.

Exicure (NASDAQ:XCUR) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.39) earnings per share (EPS) for the quarter.

Insider Activity

In other Exicure news, major shareholder Sangsangin Investment & Securi sold 433,332 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $8.71, for a total transaction of $3,774,321.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 52.80% of the company’s stock.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.